ALKS
Price
$29.06
Change
+$0.80 (+2.83%)
Updated
Aug 15, 04:59 PM (EDT)
Capitalization
4.8B
67 days until earnings call
DVAX
Price
$10.79
Change
+$0.17 (+1.60%)
Updated
Aug 15 closing price
Capitalization
1.27B
75 days until earnings call
Interact to see
Advertisement

ALKS vs DVAX

Header iconALKS vs DVAX Comparison
Open Charts ALKS vs DVAXBanner chart's image
Alkermes
Price$29.06
Change+$0.80 (+2.83%)
Volume$25.23K
Capitalization4.8B
Dynavax Technologies
Price$10.79
Change+$0.17 (+1.60%)
Volume$1.02M
Capitalization1.27B
ALKS vs DVAX Comparison Chart in %
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. DVAX commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Hold and DVAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (ALKS: $29.05 vs. DVAX: $10.79)
Brand notoriety: ALKS and DVAX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALKS: 87% vs. DVAX: 63%
Market capitalization -- ALKS: $4.8B vs. DVAX: $1.27B
ALKS [@Pharmaceuticals: Generic] is valued at $4.8B. DVAX’s [@Pharmaceuticals: Generic] market capitalization is $1.27B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 1 FA rating(s) are green whileDVAX’s FA Score has 0 green FA rating(s).

  • ALKS’s FA Score: 1 green, 4 red.
  • DVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, ALKS is a better buy in the long-term than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 4 TA indicator(s) are bullish while DVAX’s TA Score has 5 bullish TA indicator(s).

  • ALKS’s TA Score: 4 bullish, 6 bearish.
  • DVAX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DVAX is a better buy in the short-term than ALKS.

Price Growth

ALKS (@Pharmaceuticals: Generic) experienced а +8.76% price change this week, while DVAX (@Pharmaceuticals: Generic) price change was +4.45% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.

Reported Earning Dates

ALKS is expected to report earnings on Oct 22, 2025.

DVAX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.8B) has a higher market cap than DVAX($1.27B). DVAX has higher P/E ratio than ALKS: DVAX (54.60) vs ALKS (14.03). ALKS YTD gains are higher at: 1.008 vs. DVAX (-15.505). ALKS has higher annual earnings (EBITDA): 450M vs. DVAX (-40.59M). ALKS has more cash in the bank: 1.02B vs. DVAX (661M). ALKS has less debt than DVAX: ALKS (72.7M) vs DVAX (286M). ALKS has higher revenues than DVAX: ALKS (1.51B) vs DVAX (295M).
ALKSDVAXALKS / DVAX
Capitalization4.8B1.27B379%
EBITDA450M-40.59M-1,109%
Gain YTD1.008-15.505-7%
P/E Ratio14.0354.6026%
Revenue1.51B295M510%
Total Cash1.02B661M154%
Total Debt72.7M286M25%
FUNDAMENTALS RATINGS
ALKS vs DVAX: Fundamental Ratings
ALKS
DVAX
OUTLOOK RATING
1..100
1370
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
4494
SMR RATING
1..100
4093
PRICE GROWTH RATING
1..100
6258
P/E GROWTH RATING
1..100
3298
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DVAX's Valuation (72) in the Biotechnology industry is in the same range as ALKS (97). This means that DVAX’s stock grew similarly to ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (44) in the Biotechnology industry is somewhat better than the same rating for DVAX (94). This means that ALKS’s stock grew somewhat faster than DVAX’s over the last 12 months.

ALKS's SMR Rating (40) in the Biotechnology industry is somewhat better than the same rating for DVAX (93). This means that ALKS’s stock grew somewhat faster than DVAX’s over the last 12 months.

DVAX's Price Growth Rating (58) in the Biotechnology industry is in the same range as ALKS (62). This means that DVAX’s stock grew similarly to ALKS’s over the last 12 months.

ALKS's P/E Growth Rating (32) in the Biotechnology industry is significantly better than the same rating for DVAX (98). This means that ALKS’s stock grew significantly faster than DVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSDVAX
RSI
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 1 day ago
63%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 1 day ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 1 day ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
Bearish Trend 10 days ago
63%
Bearish Trend 8 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 1 day ago
68%
Aroon
ODDS (%)
Bearish Trend 2 days ago
57%
Bullish Trend 1 day ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OIEJX25.73N/A
N/A
JPMorgan Equity Income R6
DRIPX29.61N/A
N/A
The MP 63
FKASX50.48N/A
N/A
Federated Hermes Kaufmann Small Cap A
FLMAX10.04N/A
N/A
Meeder Muirfield Adviser
EPGIX15.09N/A
N/A
EuroPac Gold I

ALKS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with COLL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then COLL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
+2.80%
COLL - ALKS
37%
Loosely correlated
+1.56%
AMRX - ALKS
37%
Loosely correlated
+0.64%
PRGO - ALKS
33%
Loosely correlated
-1.43%
PAHC - ALKS
33%
Loosely correlated
+0.33%
DVAX - ALKS
32%
Poorly correlated
+1.60%
More